Combination therapies for the treatment of alzheimer's disease and related disorders

Abstract

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

1 .- 20 . (canceled) 
     
     
         21 . A method of inhibiting the formation of amyloid oligomers and/or amyloid plaques associated with Alzheimer's disease in a subject in need thereof comprising administering to the subject an effective amount of cromolyn or a salt thereof. 
     
     
         22 . The method of  claim 21 , wherein the amyloid oligomers are amyloid-β oligomers. 
     
     
         23 . The method of  claim 21 , wherein the amyloid plaques are amyloid-β plaques. 
     
     
         24 . The method of  claim 21 , wherein the subject is suffering from the early stages of Alzheimer's disease. 
     
     
         25 . The method of  claim 21 , wherein the subject is suffering from Alzheimer's disease. 
     
     
         26 . The method of  claim 21 , wherein the subject is at risk of developing Alzheimer's disease. 
     
     
         27 . The method of  claim 21 , wherein the cromolyn or salt thereof is cromolyn sodium. 
     
     
         28 . The method of  claim 21 , wherein the cromolyn or salt thereof is formulated as a dry powder for inhalation. 
     
     
         29 . The method of  claim 28 , wherein the cromolyn or salt thereof is formulated for inhalation as a dry powder of less than 3 microns in particle size. 
     
     
         30 . The method of  claim 21 , wherein the cromolyn or salt thereof is administered in an amount of about 16 mg/day or about 20 mg/day. 
     
     
         31 . A method of inhibiting the formation of amyloid oligomers and/or amyloid plaques associated with Alzheimer's disease in a subject in need thereof comprising administering to the subject an effective amount of a compound having the structure: 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         32 . The method of  claim 31 , wherein the amyloid oligomers are amyloid-β oligomers. 
     
     
         33 . The method of  claim 31 , wherein the amyloid plaques are amyloid-β plaques. 
     
     
         34 . The method of  claim 31 , wherein the subject is suffering from the early stages of Alzheimer's disease. 
     
     
         35 . The method of  claim 31 , wherein the subject is suffering from Alzheimer's disease. 
     
     
         36 . The method of  claim 31 , wherein the subject is at risk of developing Alzheimer's disease. 
     
     
         37 . The method of  claim 31 , wherein the compound or salt thereof is a sodium salt of the compound. 
     
     
         38 . The method of  claim 31 , wherein the compound or salt thereof is formulated as a dry powder for inhalation. 
     
     
         39 . The method of  claim 38 , wherein the compound or salt thereof is formulated for inhalation as a dry powder of less than 3 microns in particle size. 
     
     
         40 . The method of  claim 31 , wherein the compound or salt thereof is administered in an amount of about 16 mg/day or about 20 mg/day.